Article

CURE's Top 5 Stories: March 2019

Here are the top 5 CURE stories for March 2019.

Here are the top 5 CURE stories for March 2019.

5. FDA Approves First Immunotherapy For Breast Cancer

In early March, the Food and Drug Administration (FDA) approved the frontline combination of Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for patients with unresectable locally advanced or metastatic PD-L1—positive triple-negative breast cancer.

4. Supporting Others Who Are Dealing With Cancer

People adjusting to cancer need space, but they also need to know they are loved and cared for. Here, one survivor shares her suggestions on how to talk with someone who is coping with their own diagnosis.

3. Immune-Boosting Foods

In this new feature of CURE’s sister publication, Heal, an expert from John Theurer Cancer Center shares three recipes filled with powerful germ-fighting, health-promoting properties.

2. Blood Cancers’ Bottom Line

We take a closer look at the high out-of-pocket medical care costs that patients with blood cancer and their families face in this piece.

1. Please Stop Calling It Hospice When I’m Very Much Alive

One is meant to improve quality of life and the other is end-of-life care. Yet palliative and hospice care still continue to be confused not only by patients, but also providers, as contributor Sarah DeBord details in her latest blog.

And as always, for links to all of our top stories and more, visit curetoday.com.

Related Videos
Image of woman.
Image of Doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Image of man with grey hair.
Image of woman with blonde hair.
Related Content